Hepatectomy is an important part of hepatocellular carcinoma (HCC) treatment but postoperative recurrence limits long-term survival. Here, the authors report a phase II clinical trial investigating perioperative tislelizumab (anti-PD-1) and lenvatinib (multi tyrosine kinase inhibitor) in patients with resectable HCC with a high-risk of recurrence.
- Lu Chen
- Shujie Zhai
- Tianqiang Song
